Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Anavex Life Sciences Corporation | AVXL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 2.81 | 0.00 | 0.00 | 0.00 | 2.81 | 07:23:06 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.60 | 2.95 | 0.35 | 11.86% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Anavex Life Sciences Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 147.95M | 52.65M | $ -17.45M | -0.39 | - | 42.51M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Anavex Life Sciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVXL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.82 | 2.91 | 2.63 | 2.7554 | 230k | -0.01 | -0.35% |
| 1 Month | 3.3 | 3.75 | 2.63 | 3.1440 | 368k | -0.49 | -14.85% |
| 3 Months | 2.57 | 3.75 | 2.21 | 2.9047 | 311k | 0.24 | 9.34% |
| 6 Months | 2.98 | 4.09 | 2.21 | 3.1004 | 392k | -0.17 | -5.70% |
| 1 Year | 2.46 | 4.09 | 1.25 | 2.8314 | 351k | 0.35 | 14.23% |
| 3 Years | 3.37 | 6.64 | 1.25 | 3.7094 | 417k | -0.56 | -16.62% |
| 5 Years | 8.55 | 14.8399 | 1.25 | 4.8135 | 766k | -5.74 | -67.13% |
Anavex Life Sciences Description
| Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company operating in the United States. It is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer's disease, other central nervous systems (CNS) diseases, pain and several types of cancer. The lead compound of the company is ANAVEX 2-73 which is developed to treat Alzheimer's disease, Parkinson's disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome. The research and development pipeline of the company includes one clinical drug candidate and several compounds in various stages of the pre-clinical study. |
